Kenvue (Kenvue) ROCE % : 10.13% (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Kenvue ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Kenvue's annualized ROCE % for the quarter that ended in Dec. 2023 was 10.13%.

Kenvue ROCE % Historical Data

The historical data trend for Kenvue's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kenvue ROCE % Chart

Kenvue Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

13.78

12.84

11.16

11.14

Kenvue Quarterly Data
	Dec19	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial								9.22	10.32	12.41	10.13	9.33

Kenvue ROCE % Calculation

Kenvue's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	2548	/	( ( (27316 - 3926)	+	(27851 - 5481) )	/ 2 )
	=	2548	/	( (23390	+	22370)	/ 2 )
	=	2548	/	22880
	=	11.14 %

Kenvue's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	2244	/	( ( (27077 - 5161)	+	(27851 - 5481) )	/ 2 )
	=	2244	/	( ( 21916	+	22370 )	/ 2 )
	=	2244	/	22143
	=	10.13 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Kenvue (NYSE:KVUE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Kenvue ROCE % Related Terms

Thank you for viewing the detailed overview of Kenvue's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kenvue (Kenvue) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Kenvue Inc (NYSE:KVUE) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

J4D:Germany J4D:Germany J4D:Germany

Address

199 Grandview Road, Skillman, NJ, USA, 08558

Website

https://www.kenvue.com

Kenvue is the world's largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.

Executives

Allison Richard E Jr	director	30 FRANK LLOYD WRIGHT DR, ANN ARBOR MI 48105
Seemantini Godbole	director	1000 LOWE'S BOULEVARD, MOORESVILLE NC 28117
Bing Xie	officer: Group President, Asia Pacific	199 GRANDVIEW ROAD, SKILLMAN NJ 08558
Donna Lorenson	officer: Chief Corp Affairs Officer	199 GRANDVIEW ROAD, SKILLMAN NJ 08558
Matthew Orlando	officer: General Counsel	199 GRANDVIEW ROAD, SKILLMAN NJ 08558
Luani Alvarado	officer: Chief People Officer	199 GRANDVIEW ROAD, SKILLMAN NJ 08558
Jan Meurer	officer: Chief Growth Officer	199 GRANDVIEW ROAD, SKILLMAN NJ 08558
Carlton Lawson	officer: Group President, EMEA	199 GRANDVIEW ROAD, SKILLMAN NJ 08558
Caroline Tillett	officer: Chief Scientific Officer	199 GRANDVIEW ROAD, SKILLMAN NJ 08558
Bernardo Tavares	officer: Chief Tech & Data Officer	199 GRANDVIEW ROAD, SKILLMAN NJ 08558
Tamara Franklin	director	107 STONE CLIFF ROAD, PRINCETON NJ 08540
Betsy D Holden	director	DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kathy Widmer	officer: Group President, NALA	C/O ELIZABETH ARDEN, INC., 2400 S.W. 145 AVENUE, MIRAMAR FL 33027
Michael E Sneed	director	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Joseph J Wolk	director	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933